Aspergillus Pneumonia in Adult Patients With Acute Leukemia

Stacey Cadogan, RN, MSN, ACNP, OCN®, and Sharon Miller, CRNP, MSN, AOCNS®

Aspergillus pneumonia often is a fatal consequence of prolonged neutropenia in patients with acute leukemia. Despite prompt diagnosis and adequate antifungal therapy, mortality remains high among these patients. Recognizing early signs and symptoms, as well as risk factors, is the key to reducing morbidity and mortality.

M ost people are commonly exposed to aspergillus, a fungal organism that is present in the soil; however, disseminated and invasive forms occur most often in those who are immunocompromised (Franquet, Giménez, & Hidalgo, 2004). Aspergillus pneumonia is a potentially fatal consequence of prolonged neutropenia caused by acute leukemia and can be difficult to treat despite prompt diagnosis and adequate antibiotic therapy (Reichenberger, Habicht, Gratwohl, & Tamm, 2002). Although increasing supportive care has successfully extended life during prolonged neutropenia because of myelosuppressive drugs, this also has led to greater susceptibility to infections in patients, with an associated rise in morbidity and mortality.

Aspergillus

Aspergillus survives well in air, dust, and moisture within healthcare facilities. Any disruption of dust or air within a hospital or healthcare facility can cause a release of airborne fungal spores. Absorbent building materials, such as wallboards, function as an ideal area for fungal spores to accumulate (Centers for Disease Control and Prevention, 2003). Therefore, the occurrence of aspergillus has been directly related to building hygiene and construction work. Construction increases the concentration of aspergillus conidia in the air, and inhaled spores can lead to colonization and subsequent infection, otherwise known as invasive aspergillosis (IA) (Reichenberger et al., 2002).

Invasive Aspergillosis

Aspergillus fumigatus is the most commonly found species in aspergillus pneumonia (Latge, 1999). In a study of more than 4,000 patients with acute leukemia, the incidence of aspergillus pneumonia was 6%, of whom 39% died (Pagano et al., 2010). An intact immune system is essential to successfully combat a fungal infection. Several factors adversely affect immune defenses in patients with hematologic disease and IA, including hematologic malignancy and neutropenia associated with chemotherapy agents used in induction, consolidation, and conditioning regimens (Safdar, 2008). Prolonged neutropenia remains the greatest risk factor in developing aspergillus pneumonia. An absolute neutrophil count (ANC) of less than 500 (neutropenia) for greater than 20 days is the strongest predictive factor in diagnosing aspergillus pneumonia (Reichenberger et al., 2002).

In patients with leukemia, damaged white blood cells impair immune response, allowing for fungal colonization (Pagano et al., 2010). Tumor necrosis factor (TNF) and macrophage inflammatory protein (MIP) are important in the defense against fungal infections (Reichenberger et al., 2002). TNF is a cytokine that is naturally present in the body and causes cell death by apoptosis. MIP facilitates neutrophil and macrophage chemotaxis, as well as neutrophil and macrophage activation against invading organisms (Gao et al., 1993). In patients with neutropenia, TNF and MIP are reduced, lowering the body’s natural defenses (Reichenberger et al., 2002).

Diagnosis of Invasive Aspergillosis

The signs and symptoms of aspergillus pneumonia often are hard to distinguish from those of bacterial infections. Patients on adequate antibacterial therapy who remain persistently febrile should be evaluated for fungal pneumonia. Aspergillus infections tend to occur in the third week of neutropenia or later (Ferrara, MacDougall, & Gallagher, 2011).

Despite severe fungal infections, patients often remain afebrile with normal radiographic testing (Safdar, 2008). Therefore, radiologic imaging is of utmost importance in the diagnosis of aspergillus.